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1. Introduction 
Chronic hepatitis B (CHB) remains a major global health problem. About 400 million people 
are chronic hepatitis B carriers. CHB can affect health-related quality of life (HRQOL). 
Several anti-viral drugs are available for CHB patients. 
2. Reviews on the epidemiology, Quality of Life, and management of Chronic 
Hepatitis B (CHB) 
This chapter first reviews the epidemiology of hepatitis B virus (HBV) and recommended 
management for CHB to identify the health problems and service needs of these patients. 
The findings from studies on health-related quality of life (HRQOL) and CHB is highlighted 
to identify any knowledge gaps. Finally, available HRQOL measures are reviewed to 
determine which one is the most suitable for applications for the evaluation of Chinese CHB 
patients in Hong Kong. 
2.1 Epidemiology and management for Chronic Hepatitis B (CHB) 
2.1.1 Epidemiology and natural history of CHB 
Hepatitis B is one of the most common infectious diseases and a leading cause of death in 
the world (Lai, Ratziu, Yuen, & Roynard, 2003; Lavanchy, 2004, 2005; Maynard, 1990; 
Wright, 2006). Approximately 2 billion are infected and more than 400 million people of 
those are chronically infected with hepatitis B virus (HBV) (Fattovich, Bortolotti, & Donato, 
2008; Lai et al., 2003). Chronically infected individuals defined as those who have diagnosed 
with hepatitis B surface antigen (HBsAg) for more than six months (A S Lok & McMahon, 
2009; Maddrey, 2000). It was estimated that 75% of chronic hepatitis B (CHB) carriers were 
found in Asia and the Western Pacific regions (Gust, 1996; Maddrey, 2000; Maynard, 1990; 
Merican et al., 2000). HBV results in 500,000 to 1.2 million deaths per year caused by 
cirrhosis, liver failure or hepatocellular carcinoma (HCC) (Lavanchy, 2004, 2005). The 
incidence of HCC is increasing and is the fifth most common cancer worldwide killing 
300,000-500,000 people per year (Lavanchy, 2004). Worldwide, approximately 30% of 
cirrhosis was attributable to HBV and over half (53%) of HCC was due to HBV (Perz, 
Armstrong, Farrington, Hutin, & Bell, 2006). HBV infection accounted for more than 50% of 
HCC (65%) and cirrhosis (57%) in Western Pacific regions (Perz et al., 2006). 
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In Hong Kong, HCC is the fourth common cancer and the third leading cause of cancer 
deaths (H. A. Hong Kong Cancer Registry, 2008). In 2006, there were 1745 (1462) new cases 
(deaths) of liver cancer registered in Hong Kong, representing 7.3% (12.1%) of all cancers in 
total (H. A. Hong Kong Cancer Registry, 2008). There was a male predominance with a 
male-to-female ratio of 3:1 (Hong Kong Cancer Registry, 2006), and the age of onset is earlier 
in males (Department of Health HKSAR, 1998). The age-standardized incidence (mortality) 
rates for males and females were 29.3 (23.3) and 8.0 (6.7) per 100,000 population, 
respectively (Hong Kong Cancer Registry, 2006). HBV was significantly contributed to HCC, 
with 80% of HCC patients found to be hepatitis B carriers (Department of Health HKSAR, 
1998). Therefore, HBV infection accounts for the majority of both cirrhosis and HCC 
worldwide (Perz et al., 2006). 
The prevalence of HBV varies notably between and within countries (Custer et al., 2004; 
Gust, 1996; Lavanchy, 2004, 2005; Maddrey, 2000; Maynard, 1990). It could be categorized as 
high, intermediate and low HBV endemicity (Custer et al., 2004; Lavanchy, 2004; Maddrey, 
2000). In areas of high endemicity, ≥8% are CHB carriers and account for a total of 45% of 
the global population (Lavanchy, 2004). They include South East Asia, China including 
Hong Kong, sub-Saharan Africa and the Amazon Basin (Custer et al., 2004; Lavanchy, 2004; 
Maddrey, 2000). In areas of intermediate endemicity, such as eastern and southern Europe, 
the Middle East, Japan and part of South America, 2-7% of the population are chronic 
carriers (Custer et al., 2004; Lavanchy, 2004; Maddrey, 2000). The endemicity of HBV is low 
in most developed countries, such as North America, Northern and Western Europe and 
Australia, where less than 2% of the population are chronic carriers (Custer et al., 2004; 
Maddrey, 2000).  
Hepatitis B virus (HBV) is present in the blood, saliva, semen, vaginal secretions, menstrual 
blood, and to a lesser degree sweat, breast milk, tears and urine of infected individuals 
(Lavanchy, 2004; Wright, 2006). Since HBV is resistant to breakdown outside the body, it is 
easily transmitted through contact with infected body fluids (Lavanchy, 2004; Wright, 2006). 
Three modes of HBV transmission have been categorized as: perinatal (from an infected 
mother to her child), horizontal transmission through mucosal contact with infected blood 
or bodily fluid secretions and parenteral or percutaneous transmission (such as injection 
drug use and needlestick injury) (C. J. Chen, Wang, & Yu, 2000; Gust, 1996; Lavanchy, 2004; 
Maddrey, 2000; Wright, 2006). 
Routes of HBV transmission vary depending on the prevalence of HBV infection (Lavanchy, 
2004; Maddrey, 2000). In areas of high endemicity, perinatal transmission is the most 
common route and the majority of HBV infection is acquired during the preschool years 
(Lavanchy, 2004; Maddrey, 2000). The lifetime risk of HBV infection is greater than 60% 
(Lavanchy, 2004; Maddrey, 2000). In areas of intermediate endemicity, most HBV infection 
occurs in infant or childhood, with lifetime risk of 20-60% (Lavanchy, 2004; Maddrey, 2000). 
In areas of low endemicity, HBV infection is acquired primarily by horizontal transmission 
(between individuals) in adolescents or early adulthood, for instance, through intravenous 
drug use or unprotected sexual transmission (Lavanchy, 2004; Maddrey, 2000). The lifetime 
risk of acquiring HBV is <20% (Lavanchy, 2004; Maddrey, 2000).  
The natural history of HBV infection has three phases including immune tolerance, immune 
clearance and a residual phase (Lai et al., 2003; McMahon, 2008; Wright, 2006). The first 
phase of HBV is immune tolerance (Lai et al., 2003; McMahon, 2008; Merican et al., 2000; 
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Wright, 2006). During this phase, patients are hepatitis B e-antigen (HBeAg) positive and 
have high levels of serum HBV DNA (ranges between 107-1011 copies/mL) (Lai et al., 2003; 
McMahon, 2008; Merican et al., 2000; Wright, 2006). However, liver inflammatory disease is 
minimal or absent, with normal or minimally elevated alanine aminotransferase (ALT) level 
and minimal histological activity in the liver (Lai et al., 2003; McMahon, 2008; Merican et al., 
2000; Wright, 2006). It usually occurs in children and young adults and may last for 10-30 
years in Asian patients who acquired HBV infection during the perinatal period (Lai et al., 
2003; Merican et al., 2000; Yuen, 2007). Patients in this phase are highly contagious and can 
transmit the disease easily (Yuen, 2007). 
The second phase is immune clearance and it usually occurs when patients are aged 
between 15-35 years old (Lai et al., 2003; McMahon, 2008; Merican et al., 2000). It is 
characterized by HBeAg positive, lower level of viral replication (presented by low serum 
HBV DNA level), evaluated or fluctuating levels of ALT, moderate or severe liver 
necroinflammation and more rapid progression of fibrosis compared to the previous phase 
(Lai et al., 2003; McMahon, 2008; Merican et al., 2000). This phase may last for several weeks 
to several years (Merican et al., 2000). Liver damage has been established and the 
progression of the disease to a more advanced stage of illness such as cirrhosis depends on 
the duration of this stage (McMahon, 2008; Wright, 2006; Yuen, 2007). 
In the third phase, patients undergo HBeAg seroconversion, with loss of HBeAg and 
appearance of an antibody to HBeAg, namely anti-HBe (European Association For the study 
of the liver, 2008; Keeffe et al., 2008; Lai et al., 2003; McMahon, 2008; Merican et al., 2000; 
Wright, 2006; Yuen, 2007). This phase is usually characterized by very low or undetectable 
serum HBV DNA levels (usually 103-105 copies/mL), persistent normal ALT level and 
inactive liver histology with minimal fibrosis (European Association For the study of the 
liver, 2008; Keeffe et al., 2008; McMahon, 2008; Wright, 2006; Yuen, 2007). 
Some patients may progress to the immune phase (phase 4), with clearance of HBsAg and 
appearance of an antibody to HBsAg (anti-HBs) (Merican et al., 2000). It indicates the 
development of full immunity to HBV (Merican et al., 2000). Serum HBV DNA tends to 
become undetectable and risk of re-infection or reactivation is low (Merican et al., 2000). 
However, this phase is rare in Asian patients, but it may occur in Caucasians at the rate of 1-
2% annually which increase with time (Merican et al., 2000). 
Understanding the epidemiology and natural history of CHB infection helps us to prevent 
HBV infection and to use anti-viral treatment more effectively. There is little benefit to treat 
patients in phase 1 or phase 3 (Merican et al., 2000). Based on current clinical guidelines, the 
goal of treatment for CHB is to reduce the risk of disease progression in phase 2, aiming to 
eliminate the viral replication of HBV (Merican et al., 2000).  
Most patients with hepatitis B have no symptoms until they have developed cirrhosis or 
HCC, both of which are very debilitating conditions that can markedly decrease HRQOL. 
Patients in the advanced stages of illness often have fatigue, pain, poor appetite, jaundice, 
ascites, variceal bleeding, and impaired cognitive function(L. M. Martin, Dan, & Younossi, 
2006; L. M. Martin & Younossi, 2005), all of which may affect the patient’s physical 
functioning, work, activities of daily living, social functioning and emotions. These domains 
should be included in the evaluation of the HRQOL of CHB patients. Anti-viral treatments 
for phase 2 CHB to prevent or delay disease progression not only reduce mortality but can 
preserve HRQOL through the prevention of morbidity. 
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2.2 Health service needs of CHB patients and HRQOL 
Chronic hepatitis B (CHB) is a chronic disease that can lead to very disabling and even lethal 
complications, which require different health care services at different stages of the illness.  
2.2.1 Monitoring 
Individuals who are chronically infected with HBV require lifetime monitoring of the status 
of infection and follow-up for the development of liver complications, for instance active 
chronic hepatitis, cirrhosis and HCC (Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & 
McMahon, 2009). International guidelines recommend the initial evaluation of patients with 
CHB infection should include a thorough history, physical examination and laboratory tests 
to identify the current stage and the phases of HBV infection (Keeffe et al., 2008; Y F Liaw et 
al., 2008; A S Lok & McMahon, 2009). We also need to take into consideration family history 
of HBV and liver cancer, risk factors for co-infection and alcohol consumption (Keeffe et al., 
2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009). Laboratory investigations should 
comprise HBsAg, HBeAg and anti-HBe, quantification of viral replication by levels of HBV 
DNA, tests for co-infection with other types of hepatitis (hepatitis C virus and hepatitis D 
virus), and HIV in high-risk group (Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & 
McMahon, 2009). Liver biopsy should be considered in those infected individuals with 
elevated ALT or HBV DNA levels (Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & 
McMahon, 2009). Patients should be counseled on preventive measures against transmission 
of HBV infection through household or sexual contacts (Keeffe et al., 2008; Y F Liaw et al., 
2008). Abstinence from alcohol is highly recommended (Keeffe et al., 2008). Negative 
impacts on psychological, physical and social well being should be considered (Y F Liaw et 
al., 2008). Previous studies showed that patients with CHB had lower HRQOL scores even 
in the absence of cirrhosis or cancer (Y F Liaw et al., 2008; S C Ong, Mak, Aung, Li, & Lim, 
2008). All infected individuals with HBV infection who are not immuned to hepatitis A 
should be vaccinated according to Centers for Disease Control and Prevention (CDC) 
recommendations (Keeffe et al., 2008; A S Lok & McMahon, 2009). After initial evaluation, 
the frequency and tests of monitoring depends on the stage of illness. 
Patients with persistently normal ALT levels often have minimal histological changes and 
poor response to currently available anti-viral drugs (Y F Liaw et al., 2008). Therefore, no 
anti-viral drug therapy is recommended for this patient group (Y F Liaw et al., 2008). 
However, they should be monitored regularly and HCC surveillance may be needed. 
There is currently no consensus on frequency or type of test for monitoring. The updated 
Asia-Pacific consensus statements recommends patients with active viral replication 
should have HBV DNA level, ALT and HBeAg testing every 3 months for the first year 
and then every 3-6 months, but this is rarely feasible because of limitation in resources (Y 
F Liaw et al., 2008). The American Association for the Study of Liver Disease (AASLD) 
guidelines recommend individuals in the immune tolerant phase (stage 2) who are 
HBeAg-positive but with normal ALT should have ALT and AST tests every 3 months for 
the first year and then every 6 months (A S Lok & McMahon, 2009). Screening for HCC is 
particularly important for high-risk group, such as Asian men aged >40 years old or Asian 
women aged >50 years old, with cirrhosis and family history of severe liver disease 
(Keeffe et al., 2008; A S Lok & McMahon, 2009). 
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2.2.2 Anti-viral drug treatment 
If patients have higher serum HBV DNA levels and increased ALT levels, drug treatment is 
recommended (Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009). A liver 
biopsy is suggested before receiving drug therapy in order to evaluate the 
necroinflammatory grade and stage of fibrosis and exclude other reasons of elevated ALT 
levels (Y F Liaw et al., 2008). The ideal goal of CHB therapy is the complete eradication of 
HBV but this is still impossible. The short-term goals of CHB treatment include suppression 
of serum HBV DNA, normalization of ALT, HBeAg seroconversion and improvement in 
liver histology (European Association For the study of the liver, 2008; Keeffe et al., 2008; Y F 
Liaw et al., 2008; A S Lok & McMahon, 2009). The ultimate goal of long term treatment is to 
prevent or delay the onset of liver complications including cirrhosis and HCC, and to 
prolong survival (European Association For the study of the liver, 2008; Keeffe et al., 2008; Y 
F Liaw et al., 2008; A S Lok & McMahon, 2009). Current clinical guidelines and treatment 
algorithms focus on the suppression of viral replication to maintain serum HBV DNA at the 
lowest possible levels (European Association For the study of the liver, 2008; Keeffe et al., 
2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009). This has been shown to prevent and 
slow the progression to cirrhosis, liver failure or HCC (European Association For the study 
of the liver, 2008; Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009). 
Currently, seven drugs are available for management of CHB infection including 
lamivudine (LVD), adefovir (ADV), entecavir (ETV), telbivudine (LdT), and tenofovir (TDF) 
and interferon (IFN-α), and pegylated IFN (peg-IFN) (European Association For the study of 
the liver, 2008; Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009). The 
choice of treatment should take into account treatment efficacy, risk of developing drug 
resistance, long term safety profile, side effects, mode of administration and cost of drug 
(Fung, Lai, & Yuen, 2008). 
Interferon (IFN-α) is the first drug used for the treatment of CHB (Lai & Yuen, 2008; Yuen & 
Lai, 2001). It has to be given by injection which limits its acceptability (Jacobson, 2006). 
Standard IFN-α has been used for treatment of CHB for more than two decades (Y F Liaw et 
al., 2008; Marcellin, Asselah, & Boyer, 2005). This treatment stimulates the immune system 
to eradicate HBV (Ayoub & Keeffe, 2008; Jacobson, 2006; Y F Liaw et al., 2008; A S Lok & 
McMahon, 2009; Marcellin et al., 2005). The efficacy of standard IFN-α has been 
demonstrated to be effective in suppression of HBV replication and in inducing remission of 
liver disease in Western populations (Fung et al., 2008; Jacobson, 2006; Y F Liaw et al., 2008; 
A S Lok & McMahon, 2009; A. S. Lok et al., 1992; Yuen & Lai, 2001). Peg-IFN, in a newer 
generation of IFN, has been shown to be superior in terms of HBeAg clearance, 
normalization of ALT and HBV DNA suppression (Ayoub & Keeffe, 2008; Cooksley et al., 
2003; Fung et al., 2008; Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009; 
Zoulim & Perrillo, 2008). The advantage of standard IFN-α or peg-IFN is a definite duration of 
treatment (Ayoub & Keeffe, 2008; Fung et al., 2008; Jacobson, 2006; Lai & Yuen, 2008; Y F Liaw 
et al., 2008). Long-term effectiveness of standard IFN has shown to be inconclusive (Fung et al., 
2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009; Marcellin et al., 2005; Yuen & Lai, 2001). 
The efficacy of IFN is limited to CHB patients with high pretreatment ALT levels (Jacobson, 
2006; A S Lok & McMahon, 2009), which is uncommon for Asian CHB patients (Fung et al., 
2008). Some studies in Japanese and Chinese patients failed to demonstrate a long-term benefit 
of standard IFN therapy. However, a recent study of Taiwanese patients with a high ALT 
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pretreatment level has shown a beneficial effect on reduction of liver-related complications, for 
instance, cirrhosis and HCC (Fung et al., 2008). The occurrence of adverse event is the main 
concern. Standard IFN and peg-IFN have similar side effect profiles but is less common in peg-
IFN (A S Lok & McMahon, 2009). The most common side effect is influenza-like symptoms 
consisting of fever, chills, headache, malaise and myalgia (Jacobson, 2006; Y F Liaw et al., 2008; 
A S Lok & McMahon, 2009). Other side effects comprise fatigue, anorexia, weight loss and hair 
loss (Y F Liaw et al., 2008). Patients receiving IFN should have regular follow-up for mood 
deterioration (Jacobson, 2006). Recently, studies have focused on combination or sequential 
therapy with LVD (Y F Liaw et al., 2008). No superior effects have been found with 
combination therapy of IFN and lamivudine (LVD) (Jacobson, 2006; Y F Liaw et al., 2008). It 
reduced the risk of developing resistance.  
Lamivudine (LVD) is a nucleoside analog and the first oral anti-viral drug licensed since 
1998 for the treatment of CHB infection (Ayoub & Keeffe, 2008; Lai & Yuen, 2008). It has an 
excellent safety profile (Ayoub & Keeffe, 2008; Fung et al., 2008; Jacobson, 2006; Leung, 2008; 
Y F Liaw et al., 2008) and is the least expensive of all nucleoside analogs approved for the 
treatment of CHB (Dan, Aung, & Lim, 2008; Zoulim & Perrillo, 2008). It is effective in 
suppressing HBV DNA, normalizing ALT and HBeAg seroconversion (Dienstag et al., 1999; 
Fung et al., 2008; Lai et al., 1998; Y F Liaw et al., 2008; A S Lok & McMahon, 2009). Previous 
studies showed that LVD led to significant histological improvement and reduction in the 
progression of liver fibrosis (Ayoub & Keeffe, 2008; Dienstag et al., 1999; Lai et al., 1998; 
Leung, 2008). Long-term LVD therapy reduces the risk of developing cirrhosis and HCC in 
precirrhotic/cirrhotic and non-cirrohotic patients (Y. F. Liaw et al., 2004; Yuen et al., 2007). 
Duration of LVD therapy remains controversial in HBeAg negative CHB patients (A S Lok 
& McMahon, 2009). For patients who are HBeAg positive, LVD can be stopped 6-9 months 
after HBeAg seroconversion (A S Lok & McMahon, 2009). Hepatic flares, defined as 
increased serum ALT levels to ≥ 5 times upper normal limit, may develop on stopping LVD 
and result in hepatic decompensation (Fung et al., 2008; Y F Liaw et al., 2008). Earlier studies 
demonstrated about 50% of the patients achieved a sustained response after stopping LVD 
treatment (Y F Liaw et al., 2008). In one of the studies by Chan et al, 89 Chinese CHB 
patients with HBeAg negative received two years of LVD treatment resulted in 56% 
complete response (defined as normalization of ALT and HBV DNA level of < 104 
copies/mL) (Y F Liaw et al., 2008). The response was sustained in 26% of patients 6 months 
after stopping LVD treatment (Y F Liaw et al., 2008). The main drawback of LVD is 
development of drug resistance (Jacobson, 2006; Y F Liaw et al., 2008; Nguyen & Keeffe, 
2009; Yuen & Lai, 2001; Zoulim & Perrillo, 2008). According to a recent review, LVD drug 
resistance rates are approximately 50% after 3 years and 76% after 8 years (Ayoub & Keeffe, 
2008; Fung et al., 2008; Leung, 2008; Nguyen & Keeffe, 2009; Yuen et al., 2007). The incidence 
of drug resistance increased with the duration of therapy (Ayoub & Keeffe, 2008; Fung et al., 
2008; Jacobson, 2006; Leung, 2008). Benefits induced by LVD therapy are reduced once drug 
resistance occurs (Fung et al., 2008; Jacobson, 2006). However, even those who develop 
LVD-resistance, their treatment outcome is still better than untreated patients.  
Adedovir (ADV) is the second oral nucleoside analog approved for CHB and has been 
shown to be effective, irrespective of HBeAg status or LVD-resistance (Hadziyannis et al., 
2006; Hadziyannis et al., 2003; Lampertico et al., 2005; Leung, 2008; Marcellin et al., 2003). 
Although ADV has fairly slow action compared with other oral anti-viral treatments (in 
terms of HBAg seroconversion, normalization of ALT and suppression of HBV DNA), 
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treatment with ADV up to 5 years results in significant histologic, virologic and biochemical 
improvement (Hadziyannis et al., 2005). Currently, ADV is primarily used in patients who 
have developed resistance to LVD (Fung et al., 2008; Zoulim & Perrillo, 2008). Some studies 
have shown the addition of ADV to LVD rather than switchover to ADV monotherapy 
produced a lower rate of resistance to ADV (Lampertico et al., 2007; Manolakopoulos et al., 
2008; Rapti, Dimou, Mitsoula, & Hadziyannis, 2007; van der Poorten et al., 2007; Zoulim & 
Perrillo, 2008). Other studies have shown that ADV monotherapy in patients with LVD-
resistant was as effective for HBV DNA suppression as combination therapy (Fung et al., 
2007; Fung et al., 2008; Y F Liaw et al., 2008; Peters et al., 2004). Most guidelines 
recommended to add on ADV in LVD-resistant patients in order to minimize the 
development of ADV-resistance and maintain HBV DNA suppression in the long term 
(European Association For the study of the liver, 2008; Keeffe et al., 2008; Y F Liaw et al., 
2008; A S Lok & McMahon, 2009). ADV has a higher genetic barrier than LVD resulting in 
lower rates of resistance (Fung et al., 2008). The cumulative incidence of ADV-resistance is 
29% after 5 years of treatment in patients with HBeAg negative and about 20% in HBeAg 
positive patients (Hadziyannis et al., 2006; A S Lok & McMahon, 2009). According to a large 
trial, ADV in 10-mg doses was well tolerated and had similar safety profile as placebo 
(Hadziyannis et al., 2006). However, renal abnormalities were reported with 30 mg of ADV 
(Marcellin et al., 2003). Continued treatment of ADV up to 5 years induces a reversible 
increase in serum creatinine of more than 0.5 mg/dL (Hadziyannis et al., 2006). Therefore, 
renal function should be monitored regularly and closely (A S Lok & McMahon, 2009). 
Entecavir (ETV) is the third oral nucleoside analog licensed for CHB (Lai & Yuen, 2008). It 
was superior to LVD and ADV in rates of histologic, biochemical and virologic responses, 
irrespective of HBeAg status (T. T. Chang et al., 2006; Lai et al., 2002; Lai et al., 2006; Leung, 
2008). In a viral kinetic study ETV showed a more dramatic decline in HBV DNA levels than 
ADV (Y F Liaw et al., 2008). After 2 years of ETV treatment, no virological breakthrough 
from ETV resistance has been found (Fung et al., 2008; Lai & Yuen, 2008; Y F Liaw et al., 
2008). The rate of resistance to ETV was very low at 1.2% in treatment-naïve patients after 5 
years (Ayoub & Keeffe, 2008; European Association For the study of the liver, 2008; Lai & 
Yuen, 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009; Nguyen & Keeffe, 2009). ETV 
has demonstrated to be effective in LVD-resistant patients, but was associated with a lower 
response rate and a higher resistance rate of 39.5% after 4 years (Ayoub & Keeffe, 2008; 
Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009; Nguyen & Keeffe, 2009). 
Therefore, LVD should be discontinued when patients are switched to ETV in order to 
reduce the risk of ETV resistance (Fung et al., 2008; A S Lok & McMahon, 2009). ADV add-
on therapy may be better than ETV switching therapy for patients with LVD-resistance 
(Fung et al., 2008; Keeffe et al., 2008; A S Lok & McMahon, 2009). ETV therapy is best given 
to treatment naïve patients (Leung, 2008).  
Telbivudine (LdT) is more potent than LVD and ADV in HBV DNA suppression (H. L. Chan 
et al., 2007; Keeffe et al., 2008; Lai et al., 2005; A S Lok & McMahon, 2009). A phase III 
controlled trial showed that 60% of patients who received LdT had an undetectable HBV DNA 
level compared to those who received LVD (40%) after 2 years of treatment (Keeffe et al., 2008; 
Y. F. Liaw et al., 2009). Resistance rate increases dramatically after one year of LdT to 25.1% in 
HBeAg positive and 10.8% in HBeAg negative patients after 2 years of treatment (Y F Liaw et 
al., 2008; A S Lok & McMahon, 2009). LdT was well tolerated when used as a monotherapy 
and has a similar safety profile to LVD (Keeffe et al., 2008; Leung, 2008; A S Lok & McMahon, 
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2009). Increase in creatine kinase levels (a level of >7 times upper limit of normal (ULN)) was 
more commonly found in patients receiving LdT than LVD (7.5% vs. 3.1%) (Leung, 2008; Y F 
Liaw et al., 2008). However, it improved spontaneously with continued drug therapy. Cases of 
reversible myopathy and peripheral neuropathy have been reported (Leung, 2008; Y F Liaw et 
al., 2008; A S Lok & McMahon, 2009). Although LdT is more potent than LVD, its high 
resistance rate and cost limit its use as the first line treatment for CHB (Keeffe et al., 2008; 
Leung, 2008; Y F Liaw et al., 2008; Zoulim & Perrillo, 2008). 
Tenofovir (TDF) is an oral anti-viral drug and has been approved for the treatment of CHB 
in 2008 (Ayoub & Keeffe, 2008; A S Lok & McMahon, 2009). It belongs to the same family of 
nucleotide analogs as ADV (Ayoub & Keeffe, 2008; Keeffe et al., 2008; A S Lok & McMahon, 
2009; Zoulim & Perrillo, 2008). It has been shown to be more potent than ADV particularly 
in early suppression of HBV (Ayoub & Keeffe, 2008; Keeffe et al., 2008; Lai & Yuen, 2008; 
Leung, 2008; Marcellin et al., 2008). In a phase III clinical trial in HBeAg positive patients, 
TDF resulted in a significantly higher percentage of patients with undetectable HBV DNA 
levels compared with ADV (76% vs. 13%) after 48 weeks (Ayoub & Keeffe, 2008; Y F Liaw et 
al., 2008; Marcellin et al., 2008). No resistance mutations associated with TDF were found at 
week 48 and 72 (Ayoub & Keeffe, 2008; Keeffe et al., 2008; Lai & Yuen, 2008; Leung, 2008). 
The incidence of adverse events was similar in TDF and ADV (Ayoub & Keeffe, 2008; Keeffe 
et al., 2008). The incidence of ALT flares (>2 times baseline values) was higher in patients 
receiving TDF than those with ADV (11% vs. 4%) (Keeffe et al., 2008). Studies are still 
ongoing for long-term efficacy and safety.  
2.2.3 Screening for HCC 
As defined in the published guideline (Bruix, Sherman, & Practice Guidelines Committee, 
2005), “screening refers to an application of diagnostic tests in patients at risk for HCC, but 
in whom there is no prior reason to suspect that HCC is present”. It states clearly that 
screening is to detect the presence of HCC among the asymptomatic hepatitis B carriers. The 
ultimate goal of screening for HCC is to reduce morbidity and mortality (Bruix et al., 2005; 
Ying, 2009; Yuen & Lai, 2003). That means to detect early preclinical and early HCC that can 
be cured (resection).  
Screening for disease should fulfill certain criteria to be medically and economically 
acceptable. Wilson’s criteria are widely used to judge whether a disease should be screened 
for and they are shown as follows (Wilson & Jungner, 1968):- 
i. The condition sought should be an important health problem; 
ii. There should be an accepted treatment for patients with the recognized disease; 
iii. Facilities for diagnosis and treatment should be available; 
iv. There should be a latent or early symptomatic stage; 
v. There should be a suitable test or examination; 
vi. The test should be acceptable to the population; 
vii. The natural history of the condition should be adequately understood; 
viii. There should be an agreed policy on whom to treat as patients; 
ix. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should 
be economically balanced in relation to possible expenditure on medical care as a whole; 
x. Case-finding should be a continuing process and not a once and for all project. 
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Although there are several published guidelines for HCC screening, there is no consensus 
regarding screening for HCC (Bruix et al., 2005; Keeffe et al., 2008; Y F Liaw et al., 2008; A S 
Lok & McMahon, 2009; Omata et al., 2010). A recent AASLD practice guideline has been 
published and recommended that HBV carriers at high risk should be screened with 
ultrasound (US) every 6-12 months and alpha-fetoprotein (AFP) alone if US is not available 
(A S Lok & McMahon, 2009). Ultrasound and AFP are currently two commonly used 
screening tests for HCC (A S Lok & McMahon, 2009). High risk group is defined as Asian 
men aged >40 years old, Asian women aged >50 years old, those with cirrhosis or family 
history of severe liver disease, with persistent or intermittent ALT elevation and/or high 
HBV DNA level >2000 IU/mL (A S Lok & McMahon, 2009). On the other hand, the latest 
Asia-Pacific consensus suggested that only male HBV carriers aged 40 or above with 
cirrhosis or family history of serious liver disease should be screened with US and AFP 
every 3-6 months (Y F Liaw et al., 2008). In general, HCC screening should be considered for 
patients with cirrhosis. However, it remains unclear whether screening for HCC in an 
asymptomatic population has beneficial outcomes, what is the best screening strategy and 
whether screening is cost-effective.  
2.2.4 Health services for CHB in Hong Kong 
The Hong Kong Government provides healthcare service to patients with HBV infection, 
but resources are limited and management has to be prioritized according to the severity of 
the illness. For patients found to be CHB carriers, the frequency of monitoring and types of 
laboratory tests differed by the severity of their diseases. 
In Hong Kong, lamivudine (LVD), adefovir (ADV) and entecavir (ETV) are the standard 
antiviral drugs used for the treatment of CHB (Fung et al., 2008). Interferons are of 
doubtful use for Chinese patients (Fung et al., 2008). Telbivudine (LdT) is seldom used 
because of its cost and high resistance rate (Fung et al., 2008; Zoulim & Perrillo, 2008). The 
long-term effect of tenofovir (TDF) is unknown (Keeffe et al., 2008; Lai & Yuen, 2008; Y F 
Liaw et al., 2008). 
Anti-viral drugs are expensive and the government provides subsidy for patients with 
cirrhosis and HCC only in public service. Most CHB patients with impaired liver function 
(ILF) need to pay for their full drug cost and HBV DNA assay. The costs of anti-viral 
treatment range from HKD 1,000 to HKD 3,000 per month depending on the drug choice 
(Yeo B, 2008). Patients’ willingness to pay may influence treatment options which also 
affects the duration of treatment, effectiveness, drug resistance and side effects. Many 
patients cannot afford or are not willing to pay for treatment even though it is 
recommended by physicians. There is no policy on hepatitis B screening (Hong Kong 
(China). Dept. of Health., 1998), which is not routinely provided by the public service.  
Free printed information on hepatitis is available from the Department of Health to educate 
the public about the prevention of spread of the disease, indication for treatment and 
treatment options (Department of Health). Primary care doctors or specialists can easily 
distribute these printed information to their patients during the consultation but this not 
often done because time is limited and the evaluation of disease pathology and its 
complication take top priority. 
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a. Management of Asymptomatic Hepatitis B (AHB) carriers 
Most infected individuals are asymptomatic and CHB is usually diagnosed incidentally 
during blood donation, health assessment or when they develop liver complications such 
as cirrhosis or HCC. Asymptomatic hepatitis B (AHB) carriers may be followed-up yearly 
at General Outpatient Clinic (GOPC) or private primary care doctors with liver function 
test (LFT) and alpha fetoprotein (AFP) but many are not. According to a local study in a 
primary care setting, most of HBV carriers did not attend GOPC for following up of their 
disease (Kung, Lam, & Li, 2004). Furthermore, there were large variations in follow-up 
period and test intervals (Kung et al., 2004). It ranges from 1 to 14 months for follow-up, 2 
to 36 for blood tests, and 6 to 60 months for ultrasound (Kung et al., 2004). One month 
follow-up may be given to those who were very anxious about their condition (Kung et 
al., 2004). Since they are asymptomatic population, they do not need to take anti-viral 
treatment unless liver-related complications developed (European Association For the 
study of the liver, 2008; Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 
2009). Both HCC screening and HBV DNA assay are not available for AHB carriers. AHB 
carriers are at risk of developing cirrhosis or HCC but screening is rarely done for these 
patients (Yuen et al., 2005). 
b. Management of patients with Impaired Liver Function (ILF) 
Patients with ILF usually have close monitoring and follow-up at Specialist Outpatient 
Clinics (SOPC) with LFT and AFP tests regularly. The frequency of follow-up contact may 
vary. It is determined by a combination of variables: results of LFT, degree of viral 
replication, and need of anti-viral drug. Patients with ILF who receive drug treatment often 
need to pay for their drug costs and HBV DNA assay. Screening for HCC is not available for 
patients with ILF.  
c. Management of patients with cirrhosis or HCC 
Patients with cirrhosis or HCC have close monitoring and follow-up at Specialist Outpatient 
Clinics (SOPC) with LFT and AFP tests regularly. Patients may receive anti-viral drug free 
of charge. Screening for HCC and HBV DNA assay are available for patients with cirrhosis. 
Clinical guidelines have been established to provide guidance to healthcare providers and 
physicians for diagnosis and management of CHB infection to reduce the development of 
complications (Keeffe et al., 2008; Y F Liaw et al., 2008; A S Lok & McMahon, 2009). 
However, the following issues remain unresolved. Firstly, not the majority of infected 
individuals are identified. Secondly, many CHB patients do not receive adequate 
management and follow-up, in particular, for those who initially do not consider anti-viral 
drug treatment. Despite numerous studies on the epidemiology, natural history and 
management of CHB, little has been done on the gap in healthcare services and patients’ 
willingness to pay for their CHB treatment. Understanding patients’ perceived needs can 
help to make service more patient-centered and improve the quality of life to CHB patients. 
2.2.5 HRQOL and service utilization 
Studies have shown a significant inverse relationship between HRQOL and service 
utilization in Western population (Dominick & Ahern, 2004; Ethgen & Kahler, 2002; Nelson 
& McHorney, 1998; Parkerson & Gutman, 2000; Singh & Nelson, 2005). Nelson et al found 
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that physical functioning and mental health were important indicators of both outpatient 
visits and hospitalization for patients with chronic disease after controlling for confounding 
variables (Nelson 1998). Another study by Mulunpalo et al showed that a significant linear 
relationship between HRQOL and outpatient physician visits for working-age population in 
Finland (Mulunpalo 1997). Furthermore, Dominick et al pointed out that HRQOL can be 
valuable tools for predicting future health care for older patients with osteoarthritis 
(Dominick 2004). Poorer general health was correlated with increased likelihood of analgesic 
or anti-inflammatory use (Dominick 2004). Poor mental health was associated with 
increased likelihood of analgesic or anti-inflammatory use (Dominick 2004). 
There were several studies on the association between HRQOL and service utilization for 
Asian population (T. Chen & Li, 2009; C. L. K. Lam & Fong, 2002; Matsumura, 2000). A 
study by Matsumura in Japan found that subjects with Short Form-36 (SF-36) physical 
component summary (PCS) score below 40 were more likely to use outpatient services and 
to be hospitalized than those who had scores greater than 50 (Matsumura 2000). Subjects 
with both SF-36 physical and mental component summary scores below 40 were more likely 
to have taken sick leave than those who had scores greater than 50 (Matsumura, 2000). A 
large study in Hong Kong showed that a linear relationship between HRQOL and service 
utilization in the local Chinese population (C. L. K. Lam & Fong, 2002). Five out of eight SF-
36 scores were independent determinants of consultation rates (C. L. K. Lam & Fong, 2002). 
Role limitation due to physical problem and bodily pain were associated with 
hospitalization (C. L. K. Lam & Fong, 2002). 
A recent study assessing the effect of HRQOL on service utilization was conducted in 737 
primary care patients in Mainland China (Chen 20009). Lower HRQOL scores were 
correlated with higher service utilization rates (Chen 20009). Three out of eight SF-36 scales 
were associated with both inpatient and outpatient consultation (Chen 20009).  
Numerous studies reported on the relationship between HRQOL and service utilization for 
Western and Asian populations (T. Chen & Li, 2009; Dominick & Ahern, 2004; Ethgen & 
Kahler, 2002; C. L. K. Lam & Fong, 2002; Matsumura, 2000; Nelson & McHorney, 1998; 
Parkerson & Gutman, 2000; Singh & Nelson, 2005), but no data were available for CHB 
patients. More studies are needed to explore the effect of HRQOL on service utilization in 
patients with CHB. 
2.3 Health-related Quality of Life (HRQOL) as a health outcome measure for Chronic 
Hepatitis B (CHB) patients 
The goal of healthcare is to maintain, restore and improve health of patients. Traditionally, 
clinicians have focused primarily on ‘hard’ clinical outcomes, for instance, patient’s 
mortality and morbidity (Eisen, Locke, & Provenzale, 1999). Clinicians are more likely to 
judge the effectiveness or efficacy of a therapy in terms of survival rate, biochemical 
parameters such as liver function, viral markers, and symptoms (Eisen et al., 1999). 
Traditional clinical outcomes (i.e. morbidity and mortality) are important but they do not 
adequately reflect patients’ perceived health, feelings and the impact of illness on life. 
Health-related quality of life (HRQOL) can provide additional information on the 
effectiveness and quality of care. 
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Chronic hepatitis B (CHB) is a chronic debilitating condition that can lead to progressive 
impairment of physical and mental health as the disease progresses. Improvements in 
medical and surgical therapies in liver diseases have led to more people living with CHB. 
HRQOL should be considered an important outcome measures for assessing the impact of 
CHB and the effectiveness of treatment. The expansion from traditional clinical outcomes to 
include HRQOL outcomes will enable us to measure modern health care more sensitively 
(Younossi, 2001). HRQOL is more sensitive in capturing the effect of illness and 
interventions for those with uncomplicated disease (Bondini et al., 2007; Levy et al., 2008; 
Nokhodian, Ataei, Kassaian, Adibi, & Farajzadegan, 2009; S C Ong et al., 2008; Tan, Cheah, 
Teo, & Yang, 2008; Yi, 2006). Furthermore, HRQOL provides additional information for the 
prioritization of needs among patients with similar clinical severity defined by traditional 
clinical outcomes. The effect of an intervention on HRQOL has become a very important 
topic for both consumers and providers of health services (R. C. Martin, Eid, Scoggins, & 
McMasters, 2007; Poon et al., 2001; Yi, 2006). 
The applications of HRQOL measures can be categorized as evaluative, discriminative 
and predictive (Preedy, Watson, & Lam, 2010; Yacavone, Locke, Provenzale, & Eisen, 
2001). Evaluative measures are the most widely used in different populations or patients 
groups (Preedy et al., 2010). It is used to assess the impact of an illness, effectiveness or 
side effect of treatment, and quality of healthcare delivery (Preedy et al., 2010; Yacavone 
et al., 2001). Discriminative measures can be used to differentiate between groups in terms 
of HRQOL (Preedy et al., 2010; Yacavone et al., 2001). Predictive measures are used to 
identify people who are at risk or predict service needs for different populations or 
patient groups (Preedy et al., 2010). HRQOL measures can apply in economic evaluation 
in relation to treatment (Kanwal et al., 2005; Sun, Qin, Li, & Jiang, 2007; Takeda, Jones, 
Shepherd, Davidson, & Price, 2007; Veenstra, Spackman, Bisceglie, Kowdley, & Gish, 
2008; Yuan, Iloeje, Li, Hay, & Yao, 2008). 
The World Health Organization (WHO) states that ‘health is a state of complete physical, 
mental and social well-being’ (WHO, 1947). Well-being is the subjective perception of an 
individual’s state of living, which has a similar concept as quality of life. It is noted that 
health is only one of many determinants of a person’s quality of life, others include social 
environment, economy, religion etc. In the context of health services, the focus is on health-
related quality of life (HRQOL) in an attempt to quantify the net consequence of a disease 
and its treatment on the patient’s perception of his/her ability to live a useful and fulfilling 
life (Schipper, Clinch, & Olweny, 1996).  
In the last few decades, there has been an increasing interest in the evaluation of HRQOL in 
patient groups, including those with chronic liver disease (Foster, Goldin, & Thomas, 1998; J. 
J. Gutteling, de Man, Busschbach, & Darlington, 2007; Younossi, 2001). The number of 
articles in gastroenterology on quality of life (QOL) or HRQOL has increased significantly in 
recent decades (Foster et al., 1998; L. M. Martin et al., 2006; L. M. Martin, Sheridan, & 
Younossi, 2002; L. M. Martin & Younossi, 2005; Younossi et al., 2001; Younossi, Kiwi, 
Boparai, Price, & Guyatt, 2000). HRQOL has become standard outcome measure in patients 
with chronic liver diseases in western countries especially in patients with chronic hepatitis 
C (CHC) (Chong et al., 2003; Foster, 1999; Foster et al., 1998; Kwan et al., 2008; Spiegel et al., 
2005). It should also become an important outcome measure in CHB patients.  
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2.3.1 Impact of CHB on HRQOL 
Although numerous studies have shown significant lower health-related quality of life 
(HRQOL) scores in patients with chronic liver diseases (CLD), there is relatively little 
attention on the impact of HRQOL in patients with hepatitis B virus (HBV) because most 
data come from western populations where CHB is uncommon (J. J. Gutteling et al., 2007; L. 
M. Martin et al., 2002). In general, studies showed a significant decline in HRQOL in 
patients with hepatitis C virus (HCV) (Foster et al., 1998; Heitkemper, Jarrett, Kurashige, & 
Carithers, 2001; Koff, 1999; Kwan et al., 2008; Miller, Hiller, & Shaw, 2001; Spiegel et al., 
2005; Strauss & Dias Teixeira, 2006). Only a few papers explored the effect of CHB on 
HRQOL (Bondini et al., 2007; Levy et al., 2008; Nokhodian et al., 2009; S C Ong et al., 2008; 
Tan et al., 2008). The first paper on HRQOL of CHB was published by Foster et al in 1998, 
which evaluated the impact of chronic hepatitis C (CHC) and CHB by a generic measure of 
HRQOL, the Medical Outcomes Study Short Form-36 (SF-36) Health Survey (Foster et al., 
1998). Patients with CHB had significant lower HRQOL scores in mental health and general 
health perception aspects, but their physical related HRQOL scores were comparable to the 
healthy control (Foster et al., 1998). The results indicated patients with CHB infection did 
not have significant lower scores in physical functions but the results were limited by a very 
small sample of CHB patients (Foster et al., 1998).  
Studies with a larger sample size and patients with different stages of CHB are needed in 
order to provide more precise measures of HRQOL. One study found that CHB patients 
had similar HRQOL scores to the healthy control group, as measured by both generic 
(Short Form-36 Health Survey, SF-36) and disease-specific (Chronic Liver Disease 
Questionnaire, CLDQ) questionnaires (Bondini et al., 2007). CHB patients had lower 
HRQOL scores in only two (fatigue and worry) out of six CLDQ scales and two (physical 
functioning and vitality) out of eight SF-36 scales compared to the norm (Bondini et al., 
2007). However, health preference values (utility) of CHB patients were lower than the 
population norm (Bondini et al., 2007). 
Recently, two large studies showed that CHB infection had a negative impact on HRQOL 
(Levy et al., 2008; S C Ong et al., 2008). Asymptomatic hepatitis B (AHB) carriers, CHB 
patients with impaired liver function (ILF), and compensated cirrhosis (CC) patients had a 
small to moderate but significant effect on HRQOL, and decompensated cirrhosis (DC) and 
hepatocellular carcinoma (HCC) patients had the lowest HRQOL scores (S C Ong et al., 
2008). Ong et al demonstrated that HRQOL measured by the generic HRQOL measures, the 
SF-36 Health Survey and EQ-5D, in Chinese AHB carriers was comparable to healthy 
controls, although those with ILF and CC patients showed a significant reduction in general 
health and mental health dimensions (S C Ong et al., 2008). Patients with more advanced 
stages of CHB (DC and HCC) had the lowest HRQOL scores in all dimensions (S C Ong et 
al., 2008). The results indicated deterioration in physical health while the disease progresses 
(S C Ong et al., 2008). 
Another study by Tan et al showed that hepatitis B carriers in Singapore had good physical 
and mental health measured by both generic (SF-36 Health Survey) and disease-specific 
(Hepatitis Quality of Life Questionnaire) HRQOL measures (Tan et al., 2008). There was no 
significant difference in HRQOL between the 108 hepatitis B carriers in the study and 
general population, except in social functioning (Tan et al., 2008).  
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A recent study assessing HRQOL in patients with CHB infection was conducted using a 
disease-specific HRQOL measure (Chronic Liver Disease Questionnaire) in Iran 
(Nokhodian et al., 2009). A sample of 61 patients with CHB infection and 60 age and sex-
matched healthy control were recruited in this study (Nokhodian et al., 2009). Patients 
had lower (worse) scores in three out of six CLDQ scales, including fatigue, abdominal 
and systemic symptoms, as compared to controls (Nokhodian et al., 2009). Surprisingly, 
CHB patients had a higher score on the worry scale, i.e. less worry, than the control 
groups (Nokhodian et al., 2009). 
Findings from a multi-country study on health preference values found that health states 
related to CHB infection had significant reduction in HRQOL (Levy et al., 2008). Health 
preference is a composite HRQOL value that ranges from 0 (death) to 1 (perfect health), 
with higher scores implying better HRQOL (Brazier, Roberts, & Deverill, 2002). Patients 
with ILF and CC had a moderate impact on HRQOL with health preference values 
ranging from 0.68 to 0.80 (Levy et al., 2008). On the other hand, patients with DC or HCC 
had a stronger impact with health preference values ranging from 0.35 to 0.41 (Levy et al., 
2008). Variation in health preference values was found between countries with lower 
health preference values found in Hong Kong and Mainland China than countries (Levy 
et al., 2008). 
These studies provided some evidence on the negative HRQOL impact of CHB but they are 
limited by small sample size, inconsistent results and a lack of differentiation between CHB 
patient types (Bondini et al., 2007; Foster et al., 1998; S C Ong et al., 2008; Tan et al., 2008). 
Although studies have reported that HCC or cirrhosis patients had poorer overall HRQOL 
scores compared with the general population (Chong et al., 2003; A. A. Dan et al., 2008; S C 
Ong et al., 2008), it is still unclear whether patients with asymptomatic, CHB infection with 
or without ILF have poorer HRQOL than the general population, and whether any 
significant difference in HRQOL was found among different CHB groups. 
An analytic investigation on factors affecting HRQOL enables better targeting of 
management. Previous studies suggested that biochemical markers, socio-demographic and 
psychosocial factors did affect HRQOL in patients with CLD but it has not been fully 
examined in Chinese CHB patients (Afendy et al., 2009; Bianchi et al., 2003; J J Gutteling et 
al., 2006; Hauser, Schnur, Steder-Neukamm, Muthny, & Grandt, 2004; Hussain et al., 2001; 
Marchesini et al., 2001; Sobhonslidsuk et al., 2006; Sumskiene, Sumskas, Petrauskas, & 
Kupcinskas, 2006; Younossi et al., 2001; Younossi et al., 2000). Disease severity, as measured 
by Child-Pugh scores or stage of CHB illness (asymptomatic, impaired liver function, 
cirrhosis and HCC), was one of the commonest factors that had a negative relationship with 
HRQOL (Bianchi et al., 2003; J J Gutteling et al., 2006; Marchesini et al., 2001; Sobhonslidsuk 
et al., 2006; Sumskiene et al., 2006; Younossi et al., 2001; Younossi et al., 2000). However, 
some studies did not find any significant effect between HRQOL and disease severity 
(Hauser, Holtmann, & Grandt, 2004; Hauser, Zimmer, Schiedermaier, & Grandt, 2004). One 
large cross-sectional study in Singapore found that disease severity was an important 
determinant of HRQOL of Chinese patients with CHB, controlling for demographic 
characteristics (S C Ong et al., 2008). Unfortunately, this study did not include some 
important clinical and co-morbidity variables in regression model, for instance, duration of 
illness and chronic co-morbidity (S C Ong et al., 2008). 
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One study examining the impact of liver cirrhosis found that the presence of cirrhosis was 
associated with lower HRQOL scores (Bondini et al., 2007). But Dan et al did not find any 
significant relationship between presence of cirrhosis and HRQOL (A. A. Dan et al., 2008). 
These two studies only included a small number of patients with CHB infection (Bondini et 
al., 2007; A. A. Dan et al., 2008). More studies are needed to confirm the relationship 
between the severity of liver disease and HRQOL in patients with CHB infection. 
Liver biomarkers, such as alanine transaminase (ALT), was not found to have any 
significant association with HRQOL (Bondini et al., 2007; Hussain et al., 2001; Miller et al., 
2001), though it is an important clinical markers to assess the severity of liver and 
determine indication for treatment (Fung et al., 2008; Keeffe et al., 2008; Y F Liaw et al., 
2008; A S Lok & McMahon, 2009; McMahon, 2006). However, Kondo et al found an 
association between HRQOL and serum albumin (Kondo et al., 2007), which is a marker 
of severity of liver disease. 
Physical symptoms, for instance, joint pain, muscle cramps, itching and abdominal pain, 
were also correlated with HRQOL (J. J. Gutteling et al., 2007; Marchesini et al., 2001; 
Younossi, 2001). Fatigue was also a concern for patients with chronic liver disease (J. J. 
Gutteling et al., 2007; J J Gutteling et al., 2006).  
Anti-viral treatment may improve patients’ HRQOL (Bernstein, Kleinman, Barker, Revicki, 
& Green, 2002; S. C. Chang, Ko, Wu, Peng, & Yang, 2008; Kang, Hwang, Lee, Chang, & Lee, 
2005; McHutchison et al., 2001; Perrillo et al., 2004; Ware, Bayliss, Mannocchia, & Davis, 
1999), but side effects can be a problem (Fung et al., 2008; Keeffe et al., 2008; Y F Liaw et al., 
2008; A S Lok & McMahon, 2009). Foster et al showed that patients with HCV receiving anti-
viral treatment of 6-12 months had decreased HRQOL because of side effects (Foster, 1999). 
Other studies demonstrated a sustained response to treatment was associated with 
improved HRQOL in patients with HCV infection (Bernstein et al., 2002; S. C. Chang et al., 
2008; Kang et al., 2005; McHutchison et al., 2001; Perrillo et al., 2004; Ware et al., 1999). 
Studies are needed to confirm the effect of anti-viral treatment on HRQOL. 
Socio-demographic factors also play an important role in HRQOL, including age, gender, 
education levels, marital status and socio-economic status (J. J. Gutteling et al., 2007; L. M. 
Martin et al., 2002). Previous studies found a significant effect of age and gender on HRQOL 
in patients with chronic liver disease, including patients with CHC and CHB (J. J. Gutteling 
et al., 2007; L. M. Martin et al., 2002). Older age was associated with lower HRQOL in 
patients with chronic liver disease (Afendy et al., 2009; J J Gutteling et al., 2006; Kondo et al., 
2007; Sobhonslidsuk et al., 2006; Younossi et al., 2001), but insignificant or positive effect on 
physical or mental HRQOL (Bianchi et al., 2003; Bondini et al., 2007; A. A. Dan et al., 2008; 
Hauser, Holtmann, et al., 2004; Hauser, Zimmer, et al., 2004; Hussain et al., 2001; Sumskiene 
et al., 2006). Consistently, females were more likely to have poorer HRQOL than males 
(Afendy et al., 2009; Bianchi et al., 2003; A. A. Dan et al., 2008; J J Gutteling et al., 2006; 
Hussain et al., 2001; Sobhonslidsuk et al., 2006). This pattern is found on the general 
population as well as patients with CLD (C. L. Lam, Lauder, Lam, & Gandek, 1999; E. T. 
Lam, Lam, Lo, & Grandek, 2008). Very few data have demonstrated the effect of other socio-
demographic factors (Hauser, Holtmann, et al., 2004; Hussain et al., 2001; Sobhonslidsuk et 
al., 2006), such as education level, marital status and social class/ socio-economic status. 
Studies showed that level of education was positively correlated with HRQOL (Hussain et 
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al., 2001; Sobhonslidsuk et al., 2006). Data from Hussain et al found there was weak 
correlation between level of education and physical HRQOL (Hussain et al., 2001). On the 
other hand, another study proved that patients with lower education level had significant 
lower mental HRQOL scores (Sobhonslidsuk et al., 2006). 
Chronic co-morbidity also affected HRQOL in patients with chronic liver disease (Hauser, 
Holtmann, et al., 2004; Hauser, Zimmer, et al., 2004; Hussain et al., 2001). Hauser et al 
examined 94 patients with CHC attending a liver clinic and showed that psychiatric co-
morbidities was one of important determinant of mental component summary (MCS) score 
of SF-36 (Hauser, Zimmer, et al., 2004). The number of active co-morbidities was associated 
with the SF-36 physical component summary (PCS) score (Hauser, Zimmer, et al., 2004). 
2.3.2 HRQOL measures applicable to CHB 
Health-related quality of life (HRQOL) can be measured by generic and disease specific 
measures (M.S. Bayliss, 1999; Brown, 1999; Eisen et al., 1999; J. J. Gutteling et al., 2007; 
Yacavone et al., 2001; Younossi, 2001; Younossi & Guyatt, 1998). Generic HRQOL measures 
can be applied to different patient populations (M.S. Bayliss, 1999; Eisen et al., 1999; J. J. 
Gutteling et al., 2007; Yacavone et al., 2001; Younossi, 2001; Younossi & Guyatt, 1998). The 
advantage of using this instrument is that it can compare with other types of diseases or 
healthy control population (M.S. Bayliss, 1999; Eisen et al., 1999; J. J. Gutteling et al., 2007; 
Yacavone et al., 2001; Younossi, 2001; Younossi & Guyatt, 1998). Therefore, it is widely used 
in health services and comparative studies. However, generic measures may not detect 
small but important clinical changes specific to a particular patient group. The Medical 
Outcomes Study Short Form-36 (SF-36) is the most commonly used (J. J. Gutteling et al., 
2007; Yacavone et al., 2001; Younossi, 2001; Younossi & Guyatt, 1998). It showed in a study 
by Foster et al. that CHB patients had significant lower HRQOL scores in mental health and 
general health perception aspects, but their physical related HRQOL scores were 
comparable to the healthy control (Foster et al., 1998). Previous studies on the use of SF-36 
on CHB patients have demonstrated that patients with less severe disease had lower 
HRQOL scores in general health compared to those with general population or healthy 
controls (Bondini et al., 2007; Foster et al., 1998; S C Ong et al., 2008; Tan et al., 2008). Once 
they developed complications, lower HRQOL scores was found in both physical and mental 
health (S C Ong et al., 2008). The effectiveness of anti-viral treatment was detected by the SF-
36 in a longitudinal study on 150 Chinese CHB patients at different stages of illness 
receiving LVD treatment (Yi, 2006).  
A disease-specific measure theoretically can detect small but clinically important changes 
on HRQOL that are unique to the particular condition although it does not allow for 
comparison with the general population or other disease groups (M.S. Bayliss, 1999; Eisen 
et al., 1999; Younossi, 2001; J. J. Gutteling et al., 2007; Yacavone et al., 2001). Several 
HRQOL measures specific for chronic liver disease patients, such as the Chronic Liver 
Disease Questionnaire (CLDQ) (Younossi, Guyatt, Kiwi, Boparai, & King, 1999), the 
Hepatitis Quality of Life Questionnaire (HQLQ) (M. S. Bayliss et al., 1998), the Liver 
Disease Quality of Life Questionnaire (LDQOL) (Gralnek et al., 2000), the Liver Disease 
Symptom Index (LDSI 1.0 and 2.0) (Unal et al., 2001; van der Plas et al., 2004), the 
Hepatitis B Quality of Life (HBQOL) (Spiegel et al., 2007) and Chronic Liver Disease-
Specific Quality of Life (CLD-QOL) (Lee et al., 2007) are available. Each instrument has its 
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advantages and disadvantages. Table 1 presents the characteristics of these disease-
specific HRQOL measures.  
 
  HQLQ CLDQ LDQOL HBQOL CLD-QOL 
Author Bayliss et al Younossi et al Granlnek et al Spiegel et al  Lee et al 
Year 1998 1999 2000 2007 2007 
Country USA USA USA USA Korea 
# of items 69 29 111 31 27 
# of scales 13 6 20 6 5 
Total 
score 
No Yes Yes Yes No 
Scales 8 scales from 
SF-36
















































    
Health distress
  
    
Sleep
  
    
Loneliness
  
    
Hopelessness
  
    
Stigma of LD
  
    
Sexual 
  
Table 1. Characteristics of Disease-specific HRQOL Measures 
The Chronic Liver Disease Questionnaire (CLDQ) is the first disease-specific HRQOL 
measure for evaluating patients with chronic liver disease (CLD) developed by Younossi et 
al (Younossi et al., 1999). The CLDQ has 29 items generated by patients with chronic liver 
disease, hepatologists, and a review of literature (Younossi et al., 1999). The CLDQ has six 
scales measuring fatigue, activity, emotional function, abdominal symptoms, systemic 
symptoms and worry (Younossi et al., 1999), which captures the important problems 
associated with CHB infection and its complications. It is scored with six domain and one 
summary scores (Younossi et al., 1999). This short measure can be completed in less than 15 
minutes, a criterion for assuring a good response rate (Cella & Tulsky, 1990; McColl, 
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Christiansen, & Konig-Zahn, 1997). Patients with different types and stages of liver disease 
were included in the development and validation process supporting its broad application 
in hepatology research (Younossi et al., 1999). It has been shown to have adequate internal 
reliability, validity and sensitivity (Younossi et al., 1999). The CLDQ has been shown to be 
suitable for cross-cultural adaptation to different cultures (Ferrer et al., 2006; Hauser, 
Schnur, et al., 2004; Rucci et al., 2005; Sobhonslidsuk, Silpakit, Kongsakon, Satitpornkul, & 
Sripetch, 2004; Wu, Deng, Ji, & Yan, 2003) including Italian, German, Chinese (Mainland) 
and Thai. Recently, it has also been translated into Portuguese and Bengali (Mucci, Citero 
Vde, Gonzalez, De Marco, & Nogueira-Martins, 2010; Ray, Dutta, Basu, & De, 2010). 
However, the responsiveness of the CLDQ has not been investigated widely. Further 
research is needed to demonstrate its ability to detect change over time or with intervention. 
The other liver disease specific HRQOL measures are less widely used because they are 
either much longer or have relatively few data supporting their validity or sensitivity. The 
HQLQ developed by Bayliss has 69 items combining the generic SF-36 scales with three 
additional generic scales (positive well-being, sleep and health distress) and two hepatitis C 
specific scales (health distress and limitations because of hepatitis C ) and was intended for 
patients with chronic hepatitis C (CHC) infection (M. S. Bayliss et al., 1998). It has been 
shown to be sensitive in patients with CHC but data on patients with CHB infection are few 
(M. S. Bayliss et al., 1998). The instrument was recently translated and validated in patients 
with CHB in Singapore (S. C. Ong, Lim, & Li, 2009, 2010). The main disadvantage of the 
HQLQ is many liver disease specific symptoms, such as abdominal pain, are not addressed 
despite its length (M. S. Bayliss et al., 1998). Furthermore, significant ceiling effects of three 
scales were observed (M. S. Bayliss et al., 1998), and the instrument’s responsiveness 
remains unknown (S. C. Ong et al., 2009, 2010). 
The Liver Disease Quality of Life instrument (LDQOL) was developed by Gralnek et al 
consisting of generic and disease-specific scales with a total of 101 items (Gralnek et al., 
2000). It is not very widely used because its length limits its acceptability. It is applicable 
mainly to patients with advanced liver disease or waiting for liver transplantation 
(Casanovas et al., 2003; Dias Teixeira, de Fatima Gomes de Sa Ribeiro, & Strauss, 2005). In 
other words, it was not designed for patients with less severe liver disease. The LDQOL has 
been translated and adapted into Spanish and Catalan in transplant patients as well as 
Brazilian Portuguese in patients with chronic liver disease (Casanovas et al., 2003; Dias 
Teixeira et al., 2005). Pilot testing has supported the reliability and validity of the LDQOL 
but it has not been tested in longitudinal studies (Dias Teixeira et al., 2005; Gralnek et al., 
2000). Recently, a short form (36 items) of the liver disease quality of life instrument (SF-
LDQOL) was validated on patients with advanced liver disease (Kanwal et al., 2008). 
However, its validity may not be generalizable to patients with asymptomatic hepatitis B or 
an early stage of liver disease (Kanwal et al., 2008).  
The Liver Disease Symptom Index (LDSI) is a short instrument that consists of 18 items that 
measure nine disease-specific symptoms and the hindrance that patients experience from 
these symptoms (Unal et al., 2001; van der Plas et al., 2004). It has been validated on 374 
patients but the data on its validity and other psychometric properties on CHB patients are 
limited (Unal et al., 2001). 
The Hepatitis B Quality of Life instrument (HBQOL) is the first HRQOL measures designed 
for specifically hepatitis B patients without cirrhosis (Spiegel et al., 2007). It is a 31 items 
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questionnaire including items assessing psychological well-being, anticipation anxiety, 
vitality, disease stigma, vulnerability, and transmissibility (Spiegel et al., 2007). It has shown 
to be valid and reliable in English-speaking patients in the United States (Spiegel et al., 
2007). The validity and applicability of this instrument on CHB patients with complications 
and other cultures are not known.  
The Chronic Liver Disease-Quality of Life questionnaire (CLD-QOL) was designed to 
measure HRQOL of Asian patients with chronic liver disease, the first of its kind (Lee et al., 
2007). There are 27 items which are organized into the domains of specific symptoms, social 
function, emotional status, general symptoms and uncertain future (Lee et al., 2007). Lee et 
al found a significant difference in HRQOL scores between patients with mild stage of 
cirrhosis and moderate to severe stage of cirrhosis, supporting construct validity of CLD-
QOL (Lee et al., 2007).  Further evaluation on its psychometric properties on patients 
without cirrhosis is needed before the instrument can be applied more widely. 
2.3.3 Preference-based measure (utility) of HRQOL 
Cost-effectiveness analysis (CEA) is an area of increasing interest among researchers, 
physicians and policy makers (Sun et al., 2007). CEA is a method of summarizing the health 
benefits and resources used by health programmes, therefore policy makers can select 
among them (Russell, Gold, Siegel, Daniels, & Weinstein, 1996; Weinstein, 1990; Weinstein, 
Siegel, Gold, Kamlet, & Russell, 1996). It summarizes all programme costs and benefits 
(effectiveness), and uses economic theory to aid choice between competing health 
programmes when resources are scarce (Russell et al., 1996; Weinstein, 1990; Weinstein et 
al., 1996). CEA can express health benefits in more generic terms, such as quality adjusted 
life years (QALYs) gained (Weinstein, 1990). It provides a common unit to allow 
comparisons between different disease groups or intervention programmes (Weinstein, 
Torrance, & McGuire, 2009). This method is particularly useful in the analysis of preventive 
health programmes, such as anti-viral treatment in CHB patients (Kanwal et al., 2005; 
Sullivan et al., 2007; Sun et al., 2007; Yuan et al., 2008).  
Most HRQOL measures give a profile of domain scores that are not designed for economic 
evaluation. Treatment evaluation by profile scores may give inconsistent results and lead to 
a piecemeal understanding of the impact of an intervention because of variations in the 
effect on different domains. For example, one scale indicates a beneficial effect whereas 
other scales may give negative results. Therefore, there is a need for methods to combine 
multidimensional information in more systematic ways. Research has shown that multi-
dimensional HRQOL states can be converted to a composite preference value expressed on a 
numerical scale ranging from 0 (death) to 1 (perfect health) (Brazier et al., 2002), based on 
preference valuation by subjects from the general population (Guide to the methods of 
technology appraisal). It is possible to have negative preference for states that are worse 
than being dead (Preedy et al., 2010). 
An important application of preference based measures is a measure of effectiveness in 
health economic evaluation (Preedy et al., 2010). Quality adjusted life year (QALY) is 
increasingly used as a measure of health outcomes in the past 20 years (Neumann, 
Greenberg, Olchanski, Stone, & Rosen, 2005). QALYs give a single index combining 
morbidity and mortality and is easy to calculate if the preference of health status is known 
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(Weinstein et al., 2009). It provides a common metric to compare with different treatment 
options with the other, to compare treatment side-effects versus benefit, or to compare 
intervention programs with another one (Preedy et al., 2010; Weinstein et al., 2009). QALYs 
have been applied to different diseases or intervention programs, for instance, treatment of 
coronary heart disease and screening for breast cancer (Chan, Nallamothu, Gurm, Hayward, 
& Vijan, 2007; Wong, Kuntz, Cowling, Lam, & Leung, 2007). Information on the preference 
values of different CHB states can be combined with life years gain in the evaluation of the 
cost-effectiveness of different anti-viral treatment strategies for CHB (Kanwal et al., 2005; 
Sullivan et al., 2007; Veenstra et al., 2008; Yuan et al., 2008). 
Three most commonly used preference based measures of health are the Short Form-6D (SF-
6D), the Health Utilities Index (HUI) and the EuroQol EQ-5D (Brazier et al., 2002; Brooks, 
1996; Feeny, Furlong, Boyle, & Torrance, 1995). They are most useful for the evaluation of 
the cost-effectiveness of anti-viral treatment for CHB. Table 2 summarizes the domains of 
the commonly used generic HRQOL measures including the SF-6D, HUI and EQ-5D. They 
may give different results and interpretations because of different dimensions and methods 
of preference valuation. Preference values are also population specific that scoring 
algorithms derived from America or Europe may not apply to the Chinese. The SF-6D is the 
only measure that has been translated for and validated in the Chinese population in Hong 
Kong (C. L. K. Lam, Brazier, & McGhee, 2008). 
 
 SF-6D HUI EQ-5D
HRQOL Utility Utility Utility
Author Brazier et al Feeney et al EuroQol Group 
Year 2002 1995 1990
Country UK USA
# of  items 10 31 5
# of scales 6 8 5
Total score Yes Yes Yes
Scales Physical functioning Vision Mobility
 Role limitations Hearing Self-care
 Social functioning Speech Usual activity 
 Pain Ambulation Pain/discomfort 




Table 2. The Comparison of Content Domains among Different HRQOL Measures 
Several studies have assessed health preference in chronic liver diseases, but the majority of 
them were on chronic hepatitis C (CHC) (Chong et al., 2003; McLernon, Dillon, & Donnan, 
2008; Thein, Krahn, Kaldor, & Dore, 2005). Only two large studies evaluating health 
preference of CHB values were found in the literature (Levy et al., 2008; S C Ong et al., 
2008). The first one was a multi-center study to elicit utilities for six hypothetical states from 
infected and uninfected individuals by Levy et al (Levy et al., 2008). The results found that 
health preference values declined with disease progressing from 0.68 in uncomplicated CHB 
to 0.35 in decompensated cirrhosis (DC) (Levy et al., 2008). Patients with DC and 
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hepatocellular carcinoma (HCC) had very low preference values (Levy et al., 2008), 
indicating a strong impact of CHB. The results of Levy’s study had limitations because it 
rated preference values on disease-specific health states (Levy et al., 2008), which is in 
contrary from NICE’s recommendation that health preference should be measured by 
generic measures based on valuations by the general public (Guide to the methods of 
technology appraisal). The other study was conducted in Singapore by Ong et al, which 
found significantly lower health preference values measured by EQ-5D in patients with DC 
and HCC compared with asymptomatic hepatitis B (AHB) carriers (S C Ong et al., 2008). A 
small study on 140 patients with chronic liver diseases, with 36% having CHB found that 
patients with CHB had better health preference values than patients with other liver 
diseases (A. A. Dan et al., 2008). 
More studies on health preference values associated with each stage of CHB from AHB, to 
CHB with ILF, cirrhosis and HCC, using locally validated preference-based measures, are 
needed to provide more accurate estimates of the change in preference value with disease 
progression. Such information is useful for the evaluation the cost-effectiveness of anti-
viral treatments.  
3. Conclusion 
Hepatitis B is a significant health problem in Southern China and Hong Kong. Chronic 
hepatitis B (CHB) is a chronic disease that puts significant demand on health services. 
Regular monitoring is needed for progression of disease and development of complications. 
Anti-viral treatments may be needed for the eradication of the virus and other interventions 
are required when complications develop. Understanding the impact of illness on quality of 
life can make health care more responsive to patients’ needs. Studies have shown significant 
lower health-related quality of life (HRQOL) scores in CHB patients especially in the 
presence of complications. Data on HRQOL in patients with CHB are limited. Generic and 
disease specific measures can complement each other in the evaluation of the impact of CHB 
on HRQOL. The Chronic Liver Disease Questionnaire (CLDQ) is a liver disease-specific 
HRQOL measure applicable to patients with chronic liver disease at different stages of 
illness. It has the best face validity for adaptation to be used in Chinese patients with CHB in 
Hong Kong. There are lots of potential applications of HRQOL data of CHB patients. It can 
inform policy and practice to make health service more patient-centered. HRQOL may also 
be used as an outcome measure of effectiveness of treatment and quality of care. HRQOL 
can be converted into a preference value for the calculation of quality adjusted life year 
(QALYs) in cost-effectiveness analysis of medical intervention.  
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